AACR 2023 | Analyzing responses and mechanisms of resistance to elraglusib

Taylor Weiskittel, Mayo Clinic, Rochester, MN, comments on research elucidating resistance mechanisms to elraglusib in patients with pancreatic cancer and the role of artificial intelligence in assessing tumor genomics. A family of AKR genes were found to be upregulated in patients who progress on elraglusib, and reducing AKR expression may be a potential strategy to increase elraglusib efficacy. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.